tirzepatide 40 mg – 10 Vials Tirzepatide 40mg — 40mg/vial Reference

The FDA removed tirzepatide from its drug shortage list in late 2024, which changed the legal landscape for compounding

Rybelsus has demonstrated cardiovascular safety in clinical trials, though it's worth noting that cardiovascular risk reduction is an established benefit for some injectable GLP-1 receptor agonists rather than an approved claim for oral semaglutide specifically

(If patients are microdosing Ozempic for health reasons not related to weight loss, like for the anti-inflammatory or cognitive benefits, their timetable may look a little different.) Every surgeon has their own approach to weaning patients off of GLP-1s before surgerysome require only a three-week pauseso always follow your doctors orders

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma